Background: Adjuvant therapy with dabrafenib plus trametinib (D þ T) for 12 months significantly reduced the risk of relapse or death vs placebo (Pbo; HR, 0.47; P < .001) in patients (pts) in the COMBI-AD trial with resected BRAF V600-mutant stage III melanoma (NCT01682083), leading to the recent US FDA approval in this indication. We used a cure-rate model to estimate long-term RFS benefit and explore the association of baseline factors with RFS to better characterize pts likely to benefit from adjuvant treatment. Methods: COMBI-AD randomized pts with completely resected BRAF V600E/Kmutant stage III melanoma to receive adjuvant D (150 mg twice daily) þ T (2 mg once daily) or Pbo for 12 months. Long-term RFS (proportion of pts who did not experience an event) was estimated using a Weibull cure-rate model. Baseline covariates were analyzed using a stratified Cox regression model for RFS, with P values calculated using a Wald v 2 test. AJCC 7th edition criteria were used for pt staging at baseline.
Results: Eight hundred seventy pts were enrolled (D þ T, n ¼ 438; Pbo, n ¼ 432). The median follow-up was 2.8 years. Estimation of long-term RFS using a cure-rate model showed a 55% (95% CI, 49%-61%) long-term RFS rate in the D þ T arm vs 38% (95% CI, 33%-43%) in the Pbo arm. Evaluation of the association between baseline disease characteristics and RFS demonstrated that lower T stage, lesser nodal involvement, and a superficial spreading melanoma subtype were independently associated with better RFS (Table) . Conversely, tumor ulceration and the presence of in-transit metastases were not associated with RFS. With respect to baseline patient demographics, an association was observed between female sex and RFS benefit (P ¼ .030). 
